




# Antibacterial of Dibenzo-*p*-Dioxi-2,8-Dicarboxylic Acid Against Pathogenic Oral Bacteria *E. faecalis* ATCC 29212 Peptide Pheromones: Quorum Sensing of in vitro and in silico Study

This article was published in the following Dove Press journal:  
*Drug Design, Development and Therapy*

Dikdik Kurnia <sup>1</sup>  
Putri Rachmawati <sup>1</sup>  
Mieke H Satari <sup>2</sup>

<sup>1</sup>Department of Chemistry, Faculty of Mathematics and Natural Science, Universitas Padjadjaran, Sumedang, Indonesia; <sup>2</sup>Department of Oral Biology, Faculty of Dentistry, Universitas Padjadjaran, Sumedang, Indonesia

**Background:** Recently, it has emerged from the international scientific literature that quorum sensing (QS) is a promising way for the effective treatment of diseases caused by pathogenic bacteria. One of the crucial proteins in the QS system of Gram-positive bacteria is the pheromone. Some research has reported secondary metabolites from natural products capable of attenuating bacteria through the interruption of the quorum sensing system. One of the Indonesian herbal plants containing bioactive compounds is Sarang Semut (*Myrmecodia pendans*). A phenolic compound, dibenzo-*p*-dioxin-2,8-dicarboxylic acid, has been isolated from this plant which had antibacterial activity against *Enterococcus faecalis*. However, the molecular mechanism of it has not been known.

**Aim:** The study in question aimed to predict the molecular action of the compound *M. pendans* against some proteins that act as a signal in the mediated QS of Gram-positive bacteria, called pheromones, including PrgQ, PrgX, PrgZ, and CcfA.

**Materials and Methods:** The methods used in this in silico study were ligand-protein docking and virtual screening that were performed by some software and programs. The compound **1** and some positive controls act as ligand were subject binding to PrgQ, PrgX, PrgZ, and CcfA as proteins target, the ligands were free for blind docking. A framework was presented potency of phenolic compounds to inhibit the protein's target from its affinity binding scores.

**Results:** It was found that compound **1** was potential to inhibit all of the tested protein and gave the highest binding affinity to PrgX ( $-9.2 \text{ kcal.mol}^{-1}$ ; the site at Phe59B, Phe59B, Asn63A, and Asn63B residue) and PrgZ ( $-7.4 \text{ kcal.mol}^{-1}$ ; the site at Leu4B, Thr65A, Thr82A, Gln81A, and Val5B residue).

**Conclusion:** It is proposed that compound **1** has a good activity to inhibit *E. faecalis* through its peptide pheromones in the QS system.

**Keywords:** oral bacteria, quorum sensing, peptide pheromones, PrgQ, PrgX, PrgZ, CcfA

## Introduction

Dental caries is the most common oral disease among the population. It is a kind of serious disease that increases the quality of life. The most prevalent cause of this problem is demineralization dental hard tissues that cause a lot of people to lose their teeth.<sup>1</sup> Several factors cause this disease, one kind of bacteria that contribute to oral disease is *E. faecalis*. It is the main bacteria that cause caries, endodontic infection,

Correspondence: Dikdik Kurnia  
Department of Chemistry, Faculty of  
Mathematics and Natural Science,  
Universitas Padjadjaran, Sumedang 45363,  
Indonesia  
Tel/Fax +62-22-779-4391  
Email dikdik.kurnia@unpad.ac.id

peri-implantitis, chronic periodontitis, and failed root canal treatment involving chronic apical periodontitis.<sup>2,3</sup>

The *E. faecalis* is a Gram-positive, nonmotile, commensal member of the gut microbiota and spherical bacteria. These bacteria attend about 90% infection in humans that causes the enterococci group. It is very often found in root canals treated teeth, causes failed endodontic treated teeth, and it has emerged a multidrug resistance such as some strain *E. faecalis* are resistant rifampicin, erythromycin, and azithromycin.<sup>4-6</sup> The resistance of pathogenic bacteria against antibiotics is a serious problem for the future.<sup>7</sup> An alternative approach is needed such as finding new modes of the action of novel antibiotics.<sup>8</sup> One of the solutions to finding the novel antibiotic is a computational approach. Virtual screening is a valuable method to identify the effectiveness of lead compound activity.<sup>9</sup> With the computational and docking methods, the prediction provided by virtual screening aims the researcher to find the most appropriate set of a compound that has required bioactivity from a natural resource, in a very effective and efficient way.<sup>10,11</sup>

The antibiotic treatment eliminates vulnerable bacteria from the bacterial population, leaving resistant bacteria to grow and multiply. In the *E. faecalis*, acquired elements, including antibiotic resistance genes, are estimated to represent over 25% of its genome. Acquired and intrinsic resistance mean that *E. faecalis* shows resistance to a variety of antibiotics. Virulence-specific therapeutics could avoid the selective pressure posed by antibiotics. Therefore, alternative anti-virulence therapeutic strategies, such as inhibition of the quorum-sensing system, could be sought to target this opportunistic pathogen.<sup>12</sup>

Quorum-sensing, termed QS, is the way bacteria communicate with each other or each cell which uses specific signals to coordinate population behaviors. Its regulate some process that occurs in the cell or synchrony requirement members in their community, such as biofilm formation and dispersal, virulence factor regulation, competence development, sporulation, and many more.<sup>13,14</sup>

Pheromone is a small peptide that acts as signals in mediate of QS in Gram-positive bacteria. These signal peptides regulate a wide array of processes, including many related to host-microbe interaction, and thus many provide novel targets for therapies that interfere with communication to disrupt bacterial infection. The pCF10 is a conjugative plasmid that occurs in the conjugation system of *E. faecalis*. Some precursors and regulators that occur in this system are PrgQ, PrgX, PrgY, PrgZ, and CcfA.<sup>15</sup>

The pCF10 is divided into two types of peptide pheromones, they are cCF10 (the amino acid sequence is LVTLVFFV) and iCF10 (the amino acid sequence is AITLIFI). The cCF10 encoded by CcfA on the chromosome, while the iCF10 encoded by PrgQ on the plasmid.<sup>15,16</sup> In pCF10 peptide regulation, the positive conjugation regulated by cCF10, act as an inducer of pCF10 conjugation genes from a donor cell, while negative conjugation is regulated by iCF10, act as inhibitor peptide which represses their expression to avoid self-induction by the endogenous pheromone from the recipient cell. The resected cCF10 activities neutralized by iCF10, in the donor cell, the induction state depends on the ratio cCF10/iCF10.<sup>16</sup> The importation of the mature cCF10 peptide into the cytosol is facilitated by PrgZ.<sup>17</sup> Then, both of mature cCF10 and iCF10 compete for binds to PrgX, the master regulator of conjugation peptide from RNPP (Rap, NprR, PlcR, and PrgX) regulators family. PrgX dimer specifically binds pCF10 at two promoters in plasmid pCF10. The iCF10 stabilizes PrgX tetramer, forming a DNA loop restricting access to RNA polymerase. The cCF10 competes with iCF10 for the binding pocket of PrgX. When cCF10 binds to PrgX, it disrupts the tetramers and eventually releases; dimer binding to DNA promoters allow access of RNA polymerase.<sup>18</sup> There is no extended region of high sequence similarity between PgrX and any other known protein, including the TraA proteins.<sup>19</sup>

In therapy and drug development, effectiveness, and safety are an important point to use by humans. So, finding a lead compound and treatment method that give no side effect is needed. Natural products can be an option as a source of the active compound.<sup>20</sup> Some plants such as *Austro eupatorium inulaefolium*, *Leoheo domatiophorus* Chaowasku, *Paramignya trimera* (Oliv.) Guillaum and *Limnocitrus littoralis* (Miq.) Swingle contains an essential oil that has various biological activities including antibacterial, antiviral, antimycotic, and antitrichomonas activities.<sup>21-23</sup> Another potential plant is Sarang Semut (*Myrmecodia pendans*) or commonly known as ant nests plant is one of *Rubiciaie* family which associated with ants. This epiphytic plant is spread in tropical forests, such as Malay Peninsula, Philippines, Cambodia, Cap York, Solomon Island, Sumatra, Borneo, Toraja, Java, and especially in Papua islands.<sup>24,25</sup> Some Papuan peoples consume *M. pendans* as traditional medicine by boil dried parts of this plant, like consume tea.

Some therapeutic activity from *M. pendans* had been reported treating a variety of systemic diseases such as leukemia, heart diseases, tuberculosis, kidney, and prostate dysfunction, various allergies, migraines, rheumatism, hemorrhoid, infection diseases,<sup>26,27</sup> especially the infection that causes dental caries.<sup>27</sup> Several compounds that were isolated from *M. pendans* is a derivate of phenolic compound, and it was reported that some derivates of phenolic compounds had good antibacterial activity, especially against *Enterococcus faecalis*.<sup>28,29</sup>

In this study, it is supposed to give information about a prediction of the drug ability of antibacterial and anti-QS compounds from *M. pendans* and the prediction of the potential target proteins to which these compounds bind. Furthermore, it is hoped to be a guide for discovering novel antipathogenic agents.

## Materials and Methods

The Ligand for this research is a phenolic compound that isolated from Sarang Semut (*M. pendans*), it was characterized as dibenzo-*p*-dioxin-2,8-dicarboxylic Acid<sup>30</sup> while the positive controls were amoxicillin (CID 33613), ampicillin (CID 6249), enalapril (CID 5388962), and esomeprazole (CID 9568614).<sup>31</sup> The chemical structure and molecular formula of this ligand retrieved from the PubChem compound database (<https://www.ncbi.nlm.nih.gov/pccompound>). Some proteins were involved in quorum sensing of *E. faecalis* was used as a protein target. The protein targets were PrgQ (2grm), prgX (2AW6), PrgZ (4FAJ), and CcfA (YidC) were retrieved from UniProt knowledgebase. (<http://www.uniprot.org/>).

## In silico Characterization of the Compound I

The phenolic characteristics were confirmed using two online programs. The chemical structures of the Sarang Semut phenolic were drawn again using PubChem Sketcher V2.4 – Mozilla Firefox online to obtain their canonical SMILE. The SMILE for dibenzo-*p*-dioxin-2,8-dicarboxylic acid was retrieved from the PubChem Compound database.<sup>32</sup> Those SMILES were used to convert the chemical structure into 3D using OPEN BABEL 2.4.1 program, in PDB format.<sup>33</sup> The SMILES of the phenolic were used further in the prediction of bioactivity. The 3-D structure model of proteins target was build using the SWISS-MODEL server (<https://swissmodel.expasy.org/>) based on its canonical sequence. The model obtained fitted

**Table 1** Antibacterial Activity of Compounds from *M. pendans* and Positive Controls (in vitro Study)

Samples	Inhibition Zone (mm)	Disc Diffusion (mm in diameter)
Compound I	8.05	6.0
Amoxycillin	16.0±0.46	15.4 ± 0.50
Ampicillin	11.5±0.12	10.0 ± 0.50
Enalapril	13.0± 0.50	11.0 ± 0.40
Esomeprazole	17.3± 0.53	16.0 ± 0.50

to the template of the 3-D structure database, PDB entry – 4n0f. This model was in PDB format.<sup>34</sup>

## Molecular Docking Between PgrX/PgrQ/PgrZ/ccfA with Compound I and Positive Controls

The ligand-protein docking and virtual screening were performed using Autodock Vina in open source software PyRx 0.8.<sup>35</sup> The phenolic compound act as ligands were subject for binding to PrgQ, PrgZ, prgX, and CcfA as protein target; the ligands were free for blind docking. The most favorable free binding energy for the molecular interaction is the one that had a binding energy score that less than 1.0Å in positional root-mean-square deviation (RMSD).<sup>36</sup>

## Complex PgrX/PgrQ/PgrZ/CcfA with Compound I and Positive Controls Visualization and Analysis

The docking results were visualized using pymol and then analyzed by software protein plus.<sup>37,38</sup> Pymol showed docking poses and ligand-residue interaction in the 3D molecular picture. To show which residues bind to a ligand, proteins. plus program analyzes the protein-ligand results complex file, and then the picture of molecular interactions come

**Table 2** Prediction of Antibacterial Activity of Compounds from *M. pendans* and Positive Controls (in vitro Study)

Ligands	Binding Affinity of Ligand-Protein Complex (Kcal.mol <sup>-1</sup> )			
	PrgX	PrgQ	PrgZ	CcfA
Compound I	-9.2	-6.7	-8.6	-7.8
Amoxycillin	-7.7	-7.9	-7.3	-8.3
Ampicillin	-8.3	-6.1	-6.5	-8.3
Enalapril	-5.9	-6.8	-6.4	-6.9
Esomeprazole	-8.4	-6.7	-7.3	-7.3

**Table 3** Hydrogen Bond in Protein-Ligand from *M. pendans*

Ligands	Residues Binding at Ligand-Protein Complex			
	PrgX	PrgQ	PrgZ	CcfA
Compound 1	Asn63A Asn63B Phe59B <b>Phe59B</b>	Asn161B Ser275B	Leu4B Thr65A Thr82A <b>Gln81A Val5B</b>	Ser240A Arg72A
Amoxicillin	Arg154A Ser169A Lys173A Ser170B	Arg145A Ser169A Lys173A Ser170B	Pro200A Ala474A Asp475A Trp511A	Arg72 A Ser240A Gln243A Gly137A Met196A
Ampicillin	Asn73B Asn63B Asp185B	Glu278A Asn161A	Ser72A Thr77A	Gly137A Gln243A Ser240A Arg72A
Enalapril	Leu4E Asn161B <b>Phe86B</b>	Tyr186A Gln216A <b>Phe182A Val179A</b>	Glu160A <b>Glu484A</b> <b>Ala172A Val159A</b>	Arg72A Ala1A Ser240A <b>Ser83A</b> <b>Gly79A Ala1A</b>
Esomeprazole	Asn73A Asn68A Asp185A	Gly150B <b>Val179B</b>	Leu503A <b>Lys504A</b>	Tyr188A

**Note:** The BOLD text indicates amino residue to form hydrophobic bond with ligands, while the regular text indicates amino acid residue to form hydrophilic bond with ligands.


out in 2D structure. For the best visualization, those molecular interactions were showed in the 3D molecular picture.

## Results


Refer to the in vitro test, it was known that dibenzo-*p*-dioxin-2,8-dicarboxylic acid from *M. pendans* (hereinafter referred to as compound 1) had antibacterial activity against *E. faecalis* with the inhibition zone was 8.05 mm at in concentration of 1000  $\mu\text{g.mL}^{-1.30}$  Some positive controls which had in vitro

test were amoxicillin, ampicillin, enalapril, and esomeprazole gave antibacterial activity with their inhibition zones were  $16 \pm 0.46$ ,  $11.5 \pm 0.12$ ,  $13 \pm 0.5$  and  $17.3 \pm 0.53$  mm, respectively, with the different concentration about 5–25  $\mu\text{g.mL}^{-1.31}$

In this docking process, we used several proteins involved in QS, more precisely in the peptide pheromone signaling process, that known as PrgX, PrgQ, PrgZ dan CcfA/CcfA.<sup>5</sup> The result of docking showed in Tables 2 and 3.



**Figure 1** Binding site of compound 1 (A), amoxicillin (B), ampicillin (C), enalapril (D), esomeprazole (E) against amino acid residue from CcfA (F) proteins.




**Figure 2** Binding site of amoxicillin (A), compound I (B), ampicillin (C), enalapril (D), esomeprazole (E) against amino acid residue from PrgQ proteins (F).

## Discussion


### Bioavailability and Antibacterial Activity Prediction of Compound I and Positive Controls Through Molecular Interaction with PrgX, PrgQ, PrgZ and CcfA

Based on Table 1, it showed that compound I was given higher activity against PrgX and PrgZ than other positive controls with binding affinity value was  $-9.2 \text{ kcal.mol}^{-1}$  and  $-7.4 \text{ kcal.mol}^{-1}$ , respectively. The highest binding

affinity against PgrQ was given from amoxicillin ( $-7.9 \text{ kcal.mol}^{-1}$ ), while the highest binding affinity against CcfA was given from amoxicillin and ampicillin (both of them show the binding affinity value  $-8.3 \text{ kcal.mol}^{-1}$ ). The active site protein which binds with the compound showed in Table 2. Based on data from Table 2, majority compounds were competitive inhibitor against CcfA proteins binding to Ser240A dan Arg72A (Figure 1). Although the esomeprazole was bound to the Tyr188A site located in the same place with other compounds in CcfA proteins,



**Figure 3** Binding site of enalapril (A), compound I (B), amoxicillin (C), ampicillin (D), esomeprazole (E) against amino acid residue from PrgZ (F) proteins.




**Figure 4** Binding site of enalapril (A), compound 1 (B), amoxicillin (C), ampicillin (D), esomeprazole (E) against amino acid residue from PrgX proteins (F).

the esomeprazole is not a competitive inhibitor because it binds to a different site than other compounds.

The inhibition of CcfA by compounds will certainly prevent the cCF10 leading decrease in cCF10 production.<sup>39</sup> If the formation of pCF10 is inhibited, the induction system will be interrupted so that the interaction between bacterial cells is interrupted. In PrgQ, all compounds that were tested show their activity with the different binding site that means they were noncompetitive inhibitors against PrgQ. The highest activity against PrgQ was shown by amoxicillin with its binding affinity of  $-7.9 \text{ kcal}\cdot\text{mol}^{-1}$  and bonded at Arg145A, Ser169A, Lys173A, and Ser170B residues, while a value of binding affinity of compound 1 against PrgQ was  $-6.7 \text{ kcal}\cdot\text{mol}^{-1}$  and bonded at Asn161B and Ser275B residues (Figure 2).

Therefore, if there is an inhibition of PrgQ (iCF10 producing) the function of the conjugative precursor inhibition will be inhibited so that the spread of genes throughout the bacterial population becomes uncontrolled. Both of PrgZ and PrgX proteins, all compounds were noncompetitive inhibitors because they were bonded at different sites against the protein, and the highest affinity value was shown by compound 1 with its scores  $-8.6 \text{ kcal}\cdot\text{mol}^{-1}$  and bonded to Leu4B, Thr65A, Thr82A. The **Gln81A** and **Val5B** residues against PrgZ (Figure 3) and it was  $-9.2 \text{ kcal}\cdot\text{mol}^{-1}$  and bonded to Phe59B, **Phe59B**, Asn63A, and Asn63B residues against PrgX (Figure 4).

In pCF10 regulation, the PrgZ acts as a facilitator in the importing process of peptide signals from plasmid to cytosol. Meanwhile, the PrgX acts as a master regulator that establishes a complex with the peptide signal in the cytosol. Therefore,



**Figure 5** Chemical structure of compounds of dibenzo-p-dioxin-2,8-dicarboxylic acid (A) from *M. pendans*; positive control: amoxicillin (B), enalapril (C), ampicillin (D), and esomeprazole (E).

inhibition both of PrgZ or PrgZ will obstruct the main pCF10 regulation process and the QS system will be blocked.

Based on the data, it is obtained that compound **1** has higher activity against PrgX and PrgZ proteins than all positive controls, while the amoxicillin has the highest activity against PrgQ and CcfA proteins. The different activity and binding site from all compounds is suggested by the different structure as follow in Figure 5.

## Chemical Structure Relationship on Antibacterial Activities of Compound **1** and Positive Controls

Based on the result and the structural comparison of all compound test, it suggests that the existence of carboxyl groups give the most contribute to the activity.<sup>40</sup> Compound **1** has the most activity because it has two carboxylic acid groups while amoxicillin, ampicillin, and esomeprazole have one carboxylic group, respectively. Even though the amoxicillin and ampicillin have a similar structure, in this case, they have a different activity. The activity of amoxicillin is better than ampicillin's activity because there is a hydroxyl group of amoxicillin which suggests increasing the activity of its compound.<sup>41</sup>

Besides, pheromone inhibitors isolated from bacteria such as iPD1, iAD1, iCF10, and iAM373 have a linear peptide structure. They have a similar characteristic in which the structure of them contains hydrophobic amino acid-like Leu, Phe, Gly, Thr, and Ile that match with the part of pheromone structure.<sup>42</sup> It could be the same analogy for the interaction of compound **1** and positive control with the protein (pheromone). The part of compound **1** and the positive control structure is hydrophobic alkyl includes phenyl, methyl, etc.

## Comparison Between the Result of in vitro and in silico

The in vitro study showed that compound **1** has the lowest of inhibition zone (8.8 mm) while in silico study suggested it has the highest binding affinity against PrgX and PrgZ ( $-9.2 \text{ kcal.mol}^{-1}$  and  $-7.4 \text{ kcal.mol}^{-1}$ ). Difference result from in vitro and in silico methods are cannot be separated from the complexity of biological system factors which cannot be fully represented by a computer program. Moreover, as a nonlinear system, biological entities is also showing 'screw up behavior'.<sup>43</sup>

## Conclusion

The dibenzo-*p*-dioxin-2,8-dicarboxylic acid (compound **1**) from Sarang semut (*Myrmecodia pendans*) has a good activity to inhibit *Enterococcus faecalis* through its peptide pheromones, which cause the existence of its carboxyl groups, or in another word, compound **1** has antibacterial and anti-QS activity. The result of this study can be guidance in advance research including in vitro, in vivo, and trial clinical.

## Acknowledgments

The authors are grateful to Universitas Padjadjaran. This research was supported by Academic Leadership Grant 2019–2020 from Universitas Padjadjaran, Sumedang Indonesia.

## Disclosure

The authors report no conflicts of interest in this work.

## References

1. Veiga N, Aires D, Douglas F, et al. Dental caries: a review. *J Dent Oral Health*. 2016;2(5):1–3.
2. Wang QQ, Zhang CF, Chu CH, et al. Prevalence of *Enterococcus faecalis* in saliva and filled root canals of teeth associated with apical periodontitis. *Int J Oral Sci*. 2012;4(1):19–23. doi:10.1038/ijos.2012.17
3. E Y K, Lapesqueur LSS, Yassuda CG, et al. *Enterococcus* species in the oral cavity: prevalence, virulence factors, and antimicrobial susceptibility. *PLoS One*. 2016;11(9):1–11.
4. Flanagan D. *Enterococcus faecalis* and dental implants. *J Oral Implantol*. 2017;43(1):8–11. doi:10.1563/aaaid-joi-D-16-00069
5. Tyne DV, Martin MJ, Gilmore MS. Virulence effect of *Enterococcus faecalis* structure, function, and biology of the *Enterococcus faecalis* cytolysin. *Toxins*. 2013;5(5):895–911. doi:10.3390/toxins5050895
6. Golob M, Pete M, Kusar D, et al. Antimicrobial resistance and virulence genes in *Enterococcus faecium* and *Enterococcus faecalis* from humans and retail red meat. *Biomed Res Int*. 2019;2019:1–12. doi:10.1155/2019/2815279
7. Seethaler M, Hertlein T, Wecklein B, et al. Novel small-molecule antibacterial against Gram-positive pathogens of *Staphylococcus* and *Enterococcus* species. *Antibiotics*. 2019;8(4):1–9. doi:10.3390/antibiotics8040210
8. Usai D, Donadu M, Bua A, et al. Enhancement of antimicrobial activity of pump inhibitors associating drugs. *J Infect Dev Ctries*. 2019;13(2):162–164. doi:10.3855/jidc.11102
9. Tang YT, Marshall GR. Virtual screening for lead discovery. In: Satyanarayanajois SD, editor. *Drug Design and Discovery: Method and Protocols*. New York: Springer Science; 2011:1–22.
10. Shen J, Xu X, Cheng F, et al. Virtual screening on natural products for discovering active compound and target information. *Curr Med Chem*. 2003;10(21):2327–2342. doi:10.2174/0929867033456729
11. Lavecchia A, Giovanni CD. Virtual screening strategies in drug discovery: A critical review. *Curr Med Chem*. 2013;20(23):2839–2860. doi:10.2174/09298673113209990001
12. Ali L, Goraya MU, Arafat Y, et al. Molecular mechanism of quorum-sensing in *Enterococcus faecalis*: its role in virulence and therapeutic approaches. *Int J Mol Sci*. 2017;18(5):1–19. doi:10.3390/ijms18050960

13. Jiang Q, Chen J, Yang C, et al. Quorum sensing: a prospective therapeutic target for bacterial diseases. *Biomed Res Int*. 2019;2019:1–15.
14. Cook LC, Federle MJ. Peptide pheromone signaling in *Streptococcus* and *Enterococcus*. *FEMS Microbiol Ecol*. 2014;38(3):473–492.
15. Chen Y, Bandyopadhyay A, Kozłowicz BK. Mechanisms of peptide sex pheromone regulation of conjugation in *Enterococcus faecalis*. *Microbiology Open*. 2017;6(4):1–13. doi:10.1002/mbo3.492
16. Antiporta MH, Dunny GM. CcfA, The genetic determinant for the cCF10 peptide pheromone in *Enterococcus faecalis* OG1RF. *J Bacteriol*. 2002;184(4):1155–1162. doi:10.1128/jb.184.4.1155-1162.2002
17. Shi K, Brown CK, Gu ZY, et al. Structure of peptide sex pheromone receptor PrgX and PrgX/pheromone complexes and regulation of conjugation in *Enterococcus faecalis*. *Proceedings of the National Academy of Sciences*. 2005;102(51):18596–18601. doi:10.1073/pnas.0506163102
18. Estarda JR, Diez AE, Guarneros G, et al. The RNPP family of quorum-sensing proteins in Gram-positive bacteria. *Appl Microbiol Biotechnol*. 2010;87(3):913–923. doi:10.1007/s00253-010-2651-y
19. Kozłowicz BK, Shi K, Gu YZ, et al. Molecular basis for control of conjugation by bacterial pheromone and inhibitor peptides. *Mol Microbiol*. 2006;62(4):1–19. doi:10.1111/j.1365-2958.2006.05434.x
20. Thomford NE, Senthane DA, Rowe A, et al. Natural product for drug discover in the 21st century: innovations for novel drug discovery. *Int J Mol Sci*. 2018;19(6):1–29. doi:10.3390/ijms19061578
21. Le NT, Ho DV, Doan TQ, et al. In vitro antimicrobial activity of essential oil extracted from leaves of *Leoheo domatiophorus* chaowasku, D.T. Ngo and H.T. Le in Vietnam. *Plants*. 2020;453(9):1–14.
22. Le NT, Ho DV, Doan TQ, et al. Biological activities of essential oil from leave of *Paramigya trimera* (Oliv.) Guillaum and *Linnocitrus littoralis* (Miq.) Swingle. *Antibiotics*. 2020;207(9):1–12.
23. Bua A, Usai D, Donadu MG, et al. Antimicrobial activity of *Austroepatorium inulaefolium* (H.B.K.) against intracellular and extracellular organism. *Nat Prod Res*. 2018;23(32):2869–2871.
24. Bashari MH, Hidayat S, Ruswandi YAR, et al. The *n*-hexane fraction of *Myrmecodia pendans* inhibits cell survival and poliferation in colon cancer cell line. *Int J Pharm Pharm Sci*. 2018;10(1):108–112. doi:10.22159/ijpps.2018v10i1.21882
25. Gartika M, Pramesti HT, Kurnia D, et al. A terpenoid isolated from Sarang Semut (*Myrmecodia pendans*) bulb and it's potential for the inhibition and eradication of *Streptococcus mutans* biofilm. *BMC Complement Altern Med*. 2018;18(151):1–8. doi:10.1186/s12906-018-2213-x
26. Sudiono J, Oka CT, Trisfilha P. The scientific base of *Myrmecodia pendans* as herbal remedies. *Br J Med Med Res*. 2015;8(3):230–237. doi:10.9734/BJMMR/2015/17465
27. Gartika AM, Wartadewi, Mariam MS, et al. Antibacterial of terpenoid A from Sarang Semut (*Myrmecodia pendans*) against *Streptococcus mutans*. *Int J Chemtech Res*. 2018;11(1):228–233.
28. Engida AM, Faika S, Thi BTN, et al. Analysis of major antioxidants from extracts of *Myrmecodia pendans* by UV/visible spectrophotometer, liquid chromatography/tandem mass spectrometry, and high-performance liquid chromatography/UV techniques. *J Food Drug Anal*. 2015;23(2):303–309. doi:10.1016/j.jfda.2014.07.005
29. Pimia RH, Nohynek L, Meier C, et al. Antimicrobial properties of phenolic compounds from Berries. *J Appl Microbiol*. 2001;90(4):494–507. doi:10.1046/j.1365-2672.2001.01271.x
30. Kurnia D, Sumiarsa D, Dharsono HAD, et al. Bioactive compound isolated from Indonesian epiphytic plan of Sarang Semut and their antibacterial activity against pathogenic oral bacteria. *Nat Prod Commun*. 2017;12(8):1201–1204. doi:10.1177/1934578X1701200814
31. Selvaraj C, Sivakamavalli J, Vaseeharan B, et al. Structural elucidation of SrtA enzyme in *Enterococcus faecalis*: an emphasis on screening of potential inhibitors against the biofilm formation. *Mol Biosyst*. 2014;10(7):1775–1789. doi:10.1039/C3MB70613C
32. Ihlenfeldt WD, Bolton EE, Bryant SH. The PubChem chemical structure sketcher. *J Cheminform*. 2009;1(20):1–9. doi:10.1186/1758-2946-1-20
33. O'Boyle NM, Banck M, James CA, et al. Open babel: an open chemical toolbox. *J Cheminform*. 2011;3(33):1–14. doi:10.1186/1758-2946-3-1
34. Waterhouse A, Bertoni M, Bienert S, et al. Sarang Semut (*Myrmecodia pendans*) against *Streptococcus mutans*. *Int J Chemtech Res*. 2018;11(1):228–233.
35. Dallakyan S, Oslon AJ. Small-molecule library screening by docking with PyRx. *Methods Mol Biol*. 2015;1263:243–250.
36. Azam SS, Abbasi SW. Molecular docking studies for the identification of novel melatonergic inhibitors for acetylserotonin-*O*-methyltransferase using different docking routines. *Theor Biol Med Model*. 2013;10(63):1–16.
37. DeLano WL, Bromberg S. *Pymol User's Guide*. USA: DeLano Scientific LLC; 2004.
38. Rauf MA, Zubair S, Azhar A. Ligand docking and binding site analysis with Pymol and Autodock/Vina. *Int J Basic Appl Sci*. 2015;4(2):168–177. doi:10.14419/ijbas.v4i2.4123
39. Chandler JR, Hirt H, Dunny GM. A paracrine peptide sex pheromone also act as an autocrine signal to induce plasmid transfer and virulence factor expression in vivo. *Proc Natl Acad Sci*. 2005;102(43):15617–15622. doi:10.1073/pnas.0505545102
40. Varadwaj PK, Lahiri T. Functional group based ligand binding affinity scoring function at atomic environmental level. *Bioinformation*. 2009;3(6):268–274. doi:10.6026/97320630003268
41. Kaushik AC, Kumar S, Wei DQ, et al. Structure based virtual screening studies to identify novel potential compound for GPR142 and their relative dynamic analysis for study of type 2 diabetes. *Front Chem*. 2018;6(23):1–14. doi:10.3389/fchem.2018.00023
42. Nakayama J, Ono Y, Suzuki A. Isolation and structure of the sex pheromone inhibitor, iAM373, of *Enterococcus faecalis*. *Biosci Biotech Biochem*. 1995;59(7):1358–1359. doi:10.1271/bbb.59.1358
43. Ekins S, Mestres J, Testa B. *In silico* pharmacology for drug discovery: applications to targets and beyond. *Br J Pharmacol*. 2007;152(1):21–37. doi:10.1038/sj.bjp.0707306

## Drug Design, Development and Therapy

Dovepress

### Publish your work in this journal

Drug Design, Development and Therapy is an international, peer-reviewed open-access journal that spans the spectrum of drug design and development through to clinical applications. Clinical outcomes, patient safety, and programs for the development and effective, safe, and sustained use of medicines are a feature of the journal, which has also

been accepted for indexing on PubMed Central. The manuscript management system is completely online and includes a very quick and fair peer-review system, which is all easy to use. Visit <http://www.dovepress.com/testimonials.php> to read real quotes from published authors.

Submit your manuscript here: <https://www.dovepress.com/drug-design-development-and-therapy-journal>